Redcare Pharmacy appoints Peter Schmid von Linstow: Redcare Pharmacy stock falls 1.67 percent

Published on 10/20/2026 at 10:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Guidance rose to 16 to 18 percent on September 28, 2026. Redcare Pharmacy stock costs EUR 76.40 on October 20, 2026, 1.67 percent below Xetra close.

Leadership and growth outlook

Peter Schmid von Linstow became CEO on October 14, 2026.
Revenue growth guidance for fiscal year 2026 rose to 16 to 18 percent on September 28, 2026.
Redcare Pharmacy stock trades at EUR 76.40 at 10:35 a.m. CEST at Lang & Schwarz on October 20, 2026, 1.67 percent below the Xetra close of October 19, 2026.

Schwarzweiß-Reportagefoto einer Roboterarm-Kommissionierung von Medikamentenschachteln — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, dokumentiert Roboter-Kommissionierung unbeschrifteter Medikamentenschachteln im Versandlager, Illustration mit AI erstellt.

Redcare Pharmacy (ISIN NL0012044747) was trading at EUR 76.40 at Lang & Schwarz on October 20, 2026, down 1.67 percent versus the Xetra close of October 19, 2026 at EUR 77.70. Redcare Pharmacy appointed Peter Schmid von Linstow as a managing board member and CEO effective October 14, 2026. The leadership change arrives before the company reports its third-quarter figures.

Growth guidance sets the frame

On September 28, 2026, Redcare raised full-year 2026 total revenue growth guidance to 16 to 18 percent from 15 to 17 percent. The company also lifted its German prescription revenue outlook to EUR 730 million to EUR 760 million from EUR 680 million to EUR 720 million, while keeping adjusted EBITDA margin guidance at 2.5 to 3.0 percent, according to Yahoo Finance.

The update gives the new CEO a clear operating benchmark: Germany's prescription business is expected to grow 45 to 51 percent in fiscal year 2026. The company said preliminary prescription revenue rose 56 percent year over year in the third quarter, making execution against that range the central test for the next report.

What does the new CEO inherit?

Redcare generated EUR 853.50 million in revenue and EUR 4.70 million in net income in the second quarter of 2026, compared with EUR 849.50 million of revenue and a EUR 10.50 million net loss in the first quarter, according to Simply Wall St. The sequential improvement in reported earnings provides a measurable starting point, but the guidance range still depends heavily on prescription growth.

Three dates define the next steps

On March 31, 2026, first-quarter revenue reached EUR 849.50 million; on June 30, 2026, second-quarter revenue reached EUR 853.50 million; on September 28, 2026, Redcare lifted its full-year growth guidance to 16 to 18 percent. The next substantiated dates are October 29, 2026 for the third-quarter interim statement and November 2, 2026 for a Baader Bank virtual investor meeting, listed on the company's investor-relations page.

Stock price and valuation context

Redcare Pharmacy's market capitalization was EUR 1.5 billion as of October 20, 2026. Its 52-week range was EUR 30.20 to EUR 85.05, placing the current quote below the year's high while the upcoming report offers the next concrete test of the growth assumptions.

Redcare Pharmacy was trading at EUR 76.40 at Lang & Schwarz on October 20, 2026 at 10:35 a.m. CEST, 1.67 percent below the Xetra close of October 19, 2026 at EUR 77.70. The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.